I migliori medici per il trattamento di Basalioma - TOP-26 medici

Oltre 900 procedure oncologiche – Il Prof. Bülent Karagöz è specializzato in casi complessi come sarcoma e linfoma con oltre 20 anni di esperienza.

• Professore presso l'Università di Istanbul Okan – forma i futuri oncologi
• Si concentra sulla biologia dei tumori e sulla ricerca in immunoterapia
• Oltre 40 pubblicazioni che avanzano nel trattamento del cancro
• Responsabile dell'Oncologia presso l'Anadolu Medical Center

Il Dr. Solak è specializzato nel trattamento di diversi tipi di cancro, incluso il basalioma, con un'ampia formazione presso l'Istituto di Oncologia dell'Università di Hacettepe.

• Ha completato una borsa di studio presso l'Istituto di Oncologia dell'Università di Hacettepe
• Lavora presso Hisar Hospital Intercontinental
• Ha ricevuto formazione presso il MD Anderson Cancer Center dell'Università del Texas

Prof. Hüseyin Baloğlu is a pathology specialist at Anadolu Medical Center in Gebze, Kocaeli, Turkey. He focuses on molecular pathology, surgical pathology, and tumour biopsy and diagnostics.

Education and accreditations: MD, GATA Medical School (1986). Pathology specialty training, GATA (1992). Associate Professor (Doçent), GATA (2004). Visiting scholar at Albert Einstein College of Medicine (New York) and Heidelberg University.

Achievements: author of over 600 peer‑reviewed publications. Holds a patent in molecular diagnostics for thyroid cancer. Leads liquid biopsy and precision oncology services.

Personal Information 

Sex:  Male

Born : 1968 

Professional Experience

Gayrettepe Florence Nigthingale Hospital

Medical Oncology Department

Besiktas/Istanbul/Turkey (ongoing)

Education:

He became Professor (22/April /2016)

Medical Oncology

Attending Phys.in Gastrointestinal Oncology (January 2005 ,2009)

Istanbul University Oncology Institue,

Department of Medical Oncology

Medical Oncology Fellowship (December 2001-December2004)

Istanbul University, Istanbul Medical Faculty

Hemodialysis Traning (May1996-January1997)

Istanbul University ,bCerrahpasa Medical Faculty

Internal Medicine Residency (November 1991-November 1996)

Istanbul University ,bCerrahpasa Medical Faculty

Ege University Medical Faculty (1985-1991)

Professional Experience

February 1999-November 2001

Metropolitan Florence Nigthingale Hospital

American Cancer Center, Gayrettepe/İstanbul

April1997- October 1998

Bayraktar Dialysis Center

Güngören/ Istanbul

Membership

Turkish Medical Oncology Association

ENET(European Neuroendocrine Tumour Society)

ESMO

ASCO

Personal information

Title: Professor Doctor

Branch: Radiation Oncology

Work History:

1 GATA Military Medical Faculty

2 Gayrettepe Florence Nightingale Hospital

3 T.R. Demiroğlu Bilim University \ Associate Professor

4 T.R Demiroğlu Bilim University \ Professor

Medical Specialties and Subspecialties:

1 Head and Neck Cancers

2 Radiation Oncology

Priority treatments:

1 Prostate cancer

2 Conformal treatments

Special advanced health technologies:

1 Truebeam Stx Technology

2 Halcyons

Education

1991 - Istanbul University Istanbul Faculty of Medicine

1996 - Istanbul University Cerrahpaşa Faculty of Medicine Radiation

Oncology Specialization Training

Experience

2022 PRIVATE MEDIPOL BAHÇELİEVLER HOSPITAL

2021 - 2021 Prof. Dr. Cemil Taşçıoğlu City Hospital, Medical Oncology Clinic Education Officer

2021 - 2021 Prof. Dr. Cemil Taşçıoğlu City Hospital

2020 - 2021 Yüzüncü Yıl University Faculty of Medicine

2020 - 2021 Head of the Department of Medical Oncology, Yüzüncü Yıl University Faculty of Medicine, Assoc. Dr.  

2018 - 2021 Lecturer - Yüzüncü Yıl University Faculty of Medicine, Head of Medical Oncology Department  

2018 - 2021 Yüzüncü Yıl University Faculty of Medicine

2015 - 2018 University of Health Sciences, Okmeydanı Training and Research Hospital

2015 - 2018 University of Health Sciences, Okmeydanı Training and Research Hospital, Medical Oncology Clinic, Sub-branch assistant

2012 - 2015 Kanuni Sultan Süleyman Training and Research Hospital, Internal Medicine specialist

2012 - 2015 Suleiman the Magnificent Training and Research Hospital,

2008 - 2012 Haseki Training and Research Hospital

2006 - 2008 Kızıltepe No. 3 Health Center General Practitioner.

Education

2018

İstanbul Okmeydanı Eğitim ve Araştırma Hastanesi, Tıbbı Onkoloji

2018

İstanbul Okmeydanı Eğitim ve Araştırma Hastanesi, Tıbbı Onkoloji, İstanbul Okmeydanı Eğitim ve Araştırma Hastanesi, Tıbbı Onkoloji

2012

İstanbul Haseki Eğitim ve Araştırma Hastanesi, İç Hastalıkları, İstanbul Haseki Eğitim ve Araştırma Hastanesi, İç Hastalıkları

2012

İstanbul Haseki Eğitim ve Araştırma Hastanesi, İç Hastalıkları

2007

Uludağ Üniversitesi Tıip Fakültesi, Tıip Fakültesi, Uludağ Üniversitesi Tıip Fakültesi, Tıip Fakültesi

Il medico è un chirurgo plastico di spicco con oltre 35 anni di esperienza, specializzato in interventi post-cancro, ustioni e tumori della pelle, nonché in chirurgia della mano e maxillo-facciale per adulti e bambini.<\/p>

Ha lavorato in istituzioni prestigiose tra cui Anadolu Medical Center, Mevki Military Hospital, GATA Haydarpaşa Training Hospital, Brooke Army Medical Center e Çorlu Military Hospital.<\/p>

Ha conseguito una laurea in medicina generale presso la Facoltà di Medicina dell'Università di Istanbul e si è specializzato in Chirurgia Plastica e Ricostruttiva presso la Scuola Medica GATA di Ankara, con una borsa di studio del The University of Texas MD Anderson Cancer Center.<\/p>

Il medico ha pubblicato oltre 60 articoli e ha partecipato a oltre 100 conferenze, ed è membro di diverse società chirurgiche internazionali.<\/p>

Dr. Rahib Hasanov is a medical oncologist. He graduated from Istanbul University Cerrahpaşa Faculty of Medicine (1999–2005). He completed an internal medicine residency (2009–2013) and a medical oncology fellowship at Marmara University (2015–2018). He also completed an observership at Houston Methodist Hospital (2006–2007).

He focuses on personalized oncology. His treatments include immunotherapy, targeted therapy, and novel agents. His clinical interests include gastrointestinal, breast, lung, and genitourinary cancers.

He attends national and international conferences. He welcomes patients from Turkey, Azerbaijan, Montenegro, Georgia, Uzbekistan, the Middle East, Europe, and the United States.

Prof. Dr. Sezer Sağlam is a medical oncologist at Gayrettepe Florence Nightingale Hospital. He specializes in gastrointestinal and breast cancers. He has contributed to cancer care through research, especially with his study on the best timing for surgery after neoadjuvant therapy in rectal cancer. This work has influenced global treatment protocols.

Dr. Sağlam has led clinical trials in targeted therapies and precision medicine. His research on liver-transplanted patients with hepatocellular carcinoma was nominated for the 2024 International Best Researcher Award. He is a member of ASCO, ESMO, and ENET. Dr. Sağlam provides personalized and evidence-based oncology care.

Il Dr. Ahmet Bilici è specializzato nel trattamento dei sarcomi e del cancro ai polmoni presso il Medipol Mega University Hospital, con oltre 20 anni di esperienza.

• Esperto in oncologia medica con un focus su casi complessi
• Uno dei principali medici in Turchia per il trattamento dei sarcomi
• Lavora in un ospedale universitario di alto livello

Education and Expertise

Selcuk University Meram Faculty of Medicine - Medical Education

Dr.Abdurrahman Yurtaslan Anakara Oncology Training and Research Hospital Medical Oncology Specialization

Experience

Malatya State Hospital Internal Diseases Clinic

Ankara Oncology Hospital Medical Oncology Clinic

Erzurum Regional Training and Research Hospital Medical Oncology Clinic


AREAS OF INTEREST

Lung cancer

esophageal cancer

Gastric cancer

breast cancer

Gastrointestinal surgery

https://scholar.google.com.tr/citations?user=EDuylhoAAAAJ&hl=tr 

Il medico è un oncologo specializzato nel trattamento dei tumori al seno, ai polmoni e gastrointestinali. Attualmente, il medico pratica presso l'Ospedale Universitario Istinye Liv.

Con una carriera che si estende su molteplici istituzioni prestigiose, il medico ha servito come Specialista in Medicina Interna presso l'Ospedale Statale di Malatya, medico presso la Clinica Oncologica di Ankara e membro del Dipartimento di Oncologia presso l'Ospedale Regionale di Formazione e Ricerca di Erzurum.

Il medico si è laureato presso la Facoltà di Medicina dell'Università di Selcuk e ha ottenuto il titolo di Professore Associato nel 2016.

Assoc. Prof. Atakan Topçu, M.D., is a medical oncologist at Medipol University and Medipol Acıbadem Regional Hospital. He treats solid tumors, including lung, breast, colorectal, gastric, and neuroendocrine cancers. His work also covers targeted therapies, immunotherapy, geriatric oncology, and cancer-related malnutrition, cachexia, and sarcopenia.

He has authored more than 50 peer-reviewed papers. Recent work includes a 2024 Frontiers in Medicine study on geriatric syndromes and a 2023 Future Oncology paper on sarcopenia and anxiety in lung cancer. He has also published on the CONUT score in breast cancer and on malnutrition in HER2-negative metastatic gastric cancer.

Dr. Topçu serves on the Editorial Board of BMC Cancer. He is a member of the Turkish Society of Medical Oncology, ESMO, and the Turkish Geriatrics Society. Education and training: M.D., Uludağ University; residency in Internal Medicine, Marmara University; fellowship in Medical Oncology, Bezmialem Vakıf University.

Education and Specialization

• 2006: Kocaeli University Faculty of Medicine
• 2014: Akdeniz University Faculty of Medicine, Internal Medicine
• 2018: Akdeniz University Faculty of Medicine, Medical Oncology

Experience

• 2006 - 2008: Konya Derebucak District Hospital
• 2009 - 2015: Akdeniz University Hospital
• 2015: Antalya Kaş State Hospital
• 2015 - 2016: İnönü University Faculty of Medicine
• 2016 - 2021: Akdeniz University Hospital
• 2021 - 2023: Antalya Training and Research Hospital

Dr. Irfan Cicin is a Professor of Medical Oncology at the Trakya University Faculty of Medicine (2015–present). He has over 20 years of medical oncology experience and has held academic roles since 2010.

Education: MD, Istanbul University – Cerrahpaşa (1991–1997). Residency in Internal Medicine, Trakya University (1997–2002). Fellowship in Medical Oncology, Trakya University (2002–2004).

Practice: Medical Oncologist, Trakya University (2005–2008). Medical Oncologist, Elazığ Training and Research Hospital (2008–2010). Associate Professor of Medical Oncology, Trakya University (2010–2015). He previously served as a physician in the Turkish Air Force at Etimesgut Military Hospital (2004–2005).

PROFESSIONAL EXPERIENCE

2011-2012
Erzurum Koprukoyu State Hospital
Department: General Medicine

2012-2017
Istanbul University Cerrahpaşa Medical Faculty
Department: Internal Medicine

06/2017-10/2017
Istanbul Gaziosmanpasa Taksim Training and Research Hospital
Department: Internal Medicine

10/2017-11/2018
Istanbul University Istanbul Medical Faculty
Department: Allergy and Immunology Fellowship

2018/2022
Istanbul University Oncology Institute
Department: Medical Oncology Fellowship

2022-2023
Tekirdag City Hospital
Department: Medical Oncology Specialist

2023-present
Istanbul Medipol University Medipol Bahcelievler Private Hospital
Department: Medical Oncology Assoc. Prof.

EDUCATION

2005-2011
Medical Education
Sivas Cumhuriyet University Medical Faculty, Sivas, Turkey

2012-2017
Internal Medicine
Istanbul University Cerrahpaşa Medical Faculty, Department of Internal Medicine, Istanbul, Turkey

2017-2018
Allergy-Immunology Fellowship
Istanbul University Istanbul Medical Faculty
Department of Internal Medicine, Division of Allergy and Immunology, Istanbul, Turkey

2018-2022
Medical Oncology Fellowship
Istanbul University Oncology Institute, Department of Medical Oncology, Istanbul, Turkey

2022
ESMO Board Certification in Medical Oncology
10th September 2022 in Paris, France.

2023
Medical Oncology Assoc. Prof.
Istanbul Medipol University Department of Medical Oncology, Istanbul, Turkey

INTERNATIONAL CLINICAL TRIALS:

1. Astefania - ROCHE

• Title: A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy
• Role: Subinvestigator

2. PFİZER

• Title: A Study Of Lorlatinib Versus Crizotinib In First-Line Treatment Of Patients With ALK-Positive NSCLC
• Role: Subinvestigator

3. RECITE - AMGEN

• Title: Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Gastrointestinal, Pancreatic, or Colorectal Cancer
• Role: Subinvestigator

4. NAVIGATE - BAYER

• Title: A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors
• Role: Subinvestigator

5. RUBY - Tesaro (PRA)

• Title: A Phase 3, Randomized, Double-blind, Multicenter Study of Dostarlimab (TSR-042) Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Patients With Recurrent or Primary Advanced Endometrial Cancer
• Role: Subinvestigator

6. ENGOT-ov43/GOG-3036 - MSD

• Title: Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK001/ENGOT-ov43/GOG-3036)
• Role: Subinvestigator

7. ASTRA ZENECA

• Title: To Study Clinical Effectiveness and Safety of Olaparib Monotherapy in Metastatic Breast Cancer Patients.
• Role: Subinvestigator

8. ROSY-O - ASTRA ZENECA

• Title: Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib
• Role: Subinvestigator
•  

INTERNATIONAL PUBLICATIONS

I. Published journal articles indexed by SCI, SSCI, and AHCI

Weekly Paclitaxel in Classic Kaposi Sarcoma

• Authors: Paksoy, N., Khanmammadov, N., Doğan, İ., Ferhatoğlu, F., Ahmed, M. A., Karaman, S., & Aydiner, A.
• Journal: Medicine, 102(5)

Carboplatin Desensitization in Ovarian Carcinoma

• Authors: Paksoy, N., Khanmammadov, N., Doğan, İ., Ferhatoğlu, F., Yildiz, A., Ak, N., & Aydiner, A.
• Journal: Medicine, 101(45), e31726

High-Dose Chemotherapy for Ewing’s Sarcoma

• Authors: Paksoy, N., Ferhatoglu, F., Dogan, İ., Khanmammadov, N., Celik, A. I., Gulbas, Z., & Başaran, M.
• Journal: Medicine, 101(49), e32213

Multidrug Refractory TFE3(+) Renal Cell Carcinoma

• Authors: Paksoy, Nail, et al.
• Journal: Journal of Oncology Pharmacy Practice, 2022, 28.1: 215-221

Crizotinib Efficacy in NSCLC with MET Alterations

• Authors: Gürbüz, M., Kiliçkap, S., Bilici, A., Karadurmuş, N., Sezer, A., Şendur, M. A. N., ... & Demirkazik, A.
• Journal: Medicine, 101(50), e32368

Clinicopathological Features in ALK Mutant NSCLC

• Authors: Dogan, I., Gurbuz, M., Paksoy, N., Ferhatoglu, F., Vatansever, S., Saip, P., ... & Aydiner, A.
• Journal: Medicine, 101(34)

PSMA-Based Tumor Burden in Prostate Cancer

• Authors: HAS SIMSEK, Duygu, et al.
• Journal: Annals of Nuclear Medicine, 2021, 35.6: 680-690

Atezolizumab in Metastatic Urothelial Carcinoma

• Authors: TURAL, Deniz, et al.
• Journal: European Urology Focus, 2021, 7.5: 1061-1066

Pulmonary Sarcomatoid Carcinoma

• Authors: FERHATOGLU, Ferhat, et al.
• Journal: Oncology Research and Treatment, 2021, 44.11: 590-601

Prognostic Factors in Atezolizumab-Treated Urothelial Carcinoma

• Authors: TURAL, Deniz, et al.
• Journal: International Journal of Clinical Oncology, 2021, 26.8: 1506-1513

Atezolizumab with Chemotherapy in Small Cell Lung Cancer

• Authors: GÜRBÜZ, Mustafa, et al.
• Journal: Journal of Cancer Research and Clinical Oncology, 2022, 1-9

FOLFIRINOX vs. Gemcitabine + Nab-Paclitaxel in Pancreatic Cancer

• Authors: AY, Seval, et al.
• Journal: Journal of Chemotherapy, 2022, 1-7

Trastuzumab Emtansine in Older HER2-Positive Breast Cancer Patients

• Authors: CIL, Ibrahim, et al.
• Journal: Tumori Journal, 2022, 108.1: 19-25

Real-Life Efficacy of Osimertinib in Advanced NSCLC

• Authors: HIZAL, Mutlu, et al.
• Journal: Journal of Cancer Research and Clinical Oncology, 2022, 148.6: 1501-1508

ALK-Positive Cells Percentage and Alectinib Efficacy

• Authors: Hizal, M., Bilgin, B., Paksoy, N., Atcı, M. M., Kahraman, S., Kılıçkap, S., ... & Şendur, M. A. N.
• Journal: Journal of Cancer Research and Clinical Oncology, 149(8), 4141-4148

Real-World Data on Alectinib in ALK-Positive NSCLC

• Authors: Hizal, M., Bilgin, B., Paksoy, N., Kılıçkap, S., Atcı, M. M., Kahraman, S., ... & Şendur, M. A. N.
• Journal: Future Oncology, 18(23), 2573-2582

Prognostic Factors in Metastatic RCC with T790M Mutation

• Authors: Dogan, I., Iribas, A., Paksoy, N., Vatansever, S., & Basaran, M.
• Journal: Journal of Cancer Research and Therapeutics

FLOT Regimen in Metastatic Gastric Cancer

• Authors: Tastekin, D., Paksoy, N., Dogan, I., Ferhatoglu, F., Khanmammadov, N., Bozbey, H. U., & Karabulut, S.
• Journal: Journal of Cancer Research and Therapeutics

Desensitization Protocol in Lenalidomide Hypersensitivity Reactions

• Authors: DEMIR, Semra, et al.
• Journal: Annals of Allergy, Asthma & Immunology, 2019, 123.4: 394-397

Factors Associated with Diagnostic Skin Test Positivity in PPI Hypersensitivity

• Authors: ÖZDEMIR, Seçil Kepil, et al.
• Journal: Allergy, 2019, 74.6: 1187-1190

Efficacy of Capecitabine and Temozolomide in Neuroendocrine Tumors

• Authors: Ünal, Ç., Azizy, A., Karabulut, S., Taştekin, D., Akyıldız, A., Yaşar, S., ... & Sağlam, S.
• Journal: The Oncologist, oyad257

Subsequent Treatments in Hormone-Positive Breast Cancer Progression

• Authors: Karacin, C., Oksuzoglu, B., Demirci, A., Keskinkılıç, M., Baytemür, N. K., Yılmaz, F., ... & Hacıbekiroğlu, İ.
• Journal: BMC cancer, 23(1), 192

Termination of Trastuzumab in HER2-Positive Metastatic Breast Cancer

• Authors: Dogan, I., Aydin, E., Khanmammadov, N., Paksoy, N., Saip, P., & Aydiner, A.
• Journal: Scientific Reports, 13(1), 8779

Long-term Outcomes and Predictors of Recurrence in Node-Negative Early Stage Breast Cancer

• Authors: Dogan, I., Aydin, E., Khanmammadov, N., Paksoy, N., Ferhatoğlu, F., Ak, N., ... & Aydiner, A.
• Journal: Journal of Cancer Research and Clinical Oncology, 1-9

Prognostic Factors Influencing PFS in HER2-Positive Metastatic Breast Cancer

• Authors: Doğan, İ., Paksoy, N., Ak, N., Vatansever, S., Saip, P., & Aydıner, A.
• Journal: European Journal of Breast Health, 19(2), 128

Treatment Efficacy of Ribociclib or Palbociclib plus Letrozole in Metastatic Breast Cancer

• Authors: Kahraman, S., Erul, E., Seyyar, M., Gumusay, O., Bayram, E., Demirel, B. C., ... & Nahit Sendur, M. A.
• Journal: Future Oncology, 19(10), 727-736

Efficacy and Safety of Sorafenib in Adult Metastatic Osteosarcoma Patients

• Authors: Dogan, I., Paksoy, N., & Basaran, M.
• Journal: Journal of Cancer Research and Therapeutics

Single-Agent Temozolomide as Salvage Therapy in Heavily Pretreated Metastatic Sarcoma Patients

• Authors: Dogan, I., Paksoy, N., & Basaran, M.
• Journal: Journal of Cancer Research and Therapeutics

Outcomes and Prognostic Factors in Metastatic Renal Cell Carcinoma with Brain Metastases

• Authors: Dogan, I., Iribas, A., Paksoy, N., Vatansever, S., & Basaran, M.
• Journal: Journal of Cancer Research and Therapeutics

FLOT Regimen in First-Line Treatment of Metastatic Gastric Cancer

• Authors: Tastekin, D., Paksoy, N., Dogan, I., Ferhatoglu, F., Khanmammadov, N., Bozbey, H. U., & Karabulut, S.
• Journal: Journal of Cancer Research and Therapeutics

Prognostic Factors of Perioperative FLOT Regimen in Operable Gastric Cancer

• Authors: Erol, C., Sakin, A., Basoglu, T., Ozden, E., Cabuk, D., Dogan, M., ... & Sendur, M. A. N.
• Journal: [Not specified]

Efficacy and Outcomes of Systemic Chemotherapy in Posttransplant Kaposi Sarcoma

• Authors: Khanmammadov, N., Paksoy, N., Doğan, I., Ferhatoğlu, F., Saip, P., & Aydiner, A.
• Journal: Medicine, 102(39), e35383

Comparison of Second-Line Treatments in Metastatic Renal Cell Carcinoma

• Authors: Pehlivan, M., Paksoy, N., Aydin, E., Basaran, M., & Ekenel, M.
• Journal: Medicine, 102(41), e35245

Toxicity Management and Effectiveness of Regorafenib in Advance GIST Patients: A Real-world Study - Authors: Paksoy, N., Ferhatoğlu, F., Doğan, İ., Khanmammadov, N., Bozbey, H. U., Karabulut, S., & Taştekin, D. - Journal: TURKISH JOURNAL OF ONCOLOGY, 1(1)

Demographic and Clinical Features and Factors Associated with Survival in Patients with Primary Glomerulonephritis: Single Tertiary Center Experience - Authors: Paksoy, N., Trabulus, S., Seyahi, N., & Altiparmak, M. R. - Journal: Namik Kemal Tip Dergisi, 11(1)

Efficacy of Sorafenib in Symptomatic Patients with Pretreated Progressive Desmoid Tumors - Authors: Paksoy, N., Ferhatoglu, F., Dogan, I., Ak, N., Pehlivan, M., Ekenel, M., & Basaran, M.

Nodal Response to Neoadjuvant Chemotherapy is a Better Predictive Factor of Survival Than Miller-Payne Scoring in Breast Cancer - Authors: Ak, Naziye, et al. - Journal: Journal of Oncological Sciences, 7.2: 42-49

Evaluation of Prognostic and Predictive Values of Hemogram Parameters in Patients with Advanced Stage Ovarian Carcinoma - Authors: Ak, Naziye, et al. - Journal: Turkish Journal of Oncology/Türk Onkoloji Dergisi, 2021, 36.4

Identifying Risk Factors Associated with Survival and Drug-Related Toxicities in Imatinib-Resistant Gastrointestinal Stromal Tumor (GIST) Patients Treated with Sunitinib - Authors: Ferhatoglu, F., Karabulut, S., Paksoy, N., & Tastekin, D.

Real-life Outcomes of ROS1 Fusion-positive Metastatic Lung Cancer Patients who were Treated with Crizotinib - Authors: Dogan, İ., Khanmammadov, N., Paksoy, N., Ferhatoglu, F., Aydın, E., Vatansever, S., & Aydine, A. - Journal: TURK ONKOLOJI DERGISI-TURKISH JOURNAL OF ONCOLOGY

Predictors of the acquisition of T790M mutation in EGFR-mutant metastatic lung cancer patients who were treated with EGFR inhibitors - Authors: Dogan, I., Khanmammadov, N., Paksoy, N., Vatansever, S., Saip, P., & Aydıner, A. - Journal: Eurasian Journal of Pulmonology

Laterality of Adrenal Gland Metastasis in Lung Cancer: Results of a Comparative Study - Authors: Ferhatoglu, F., Gagatay, T., Okumus, G., Aydiner, A., Paksoy, N., Ak, N., ... & Saip, P. - Journal: Eurasian Journal of Medical Investigation, 7(2)

Poor Risk Factors Affecting Cancer Patients Infected with Covid-19: A Retrospective Comparative Study from a Pandemic Hospital - Authors: Ferhatoglu, F., Kapağan, T., Paksoy, N., Ak, N., Medetalibeyoğlu, A., Şenkal, N., ... & Vatansever, S. - Journal: Turk Onkoloji Dergisi, 38(1)

Systemic Treatment Outcomes of Progressive Medullary Thyroid Carcinoma from the Registries of a Tertiary Cancer Center - Authors: Ferhatoglu, F., Paksoy, N., & Başaran, M. - Journal: Namik Kemal Tip Dergisi, 10(4)

Evaluation of clinical features and risk factors related to late recurrence (> 5 years) in patients with breast cancer - Authors: Ferhatoglu, F., Aydiner, A., & Paksoy, N. - Journal: Journal of Surgery & Medicine (JOSAM), 6(12)

Assessing the Clinical Impact of Lutetium-177 DOTATATE Peptide Receptor Radionuclide Therapy (PRRT) on Metastatic Neuroendocrine Tumors: A Multicenter Real-World Data from Türkiye

Thesis:

Istanbul University Cerrahpaşa Medical Faculty, Internal Medicine Department PAKSOY, Nail. Demographical, clinical characteristics and survival factors in patients withprimary glomerulonephritis: Cerrahpasa Medical Faculty Experience. (2016)

International Refereed Congress / Symposium Publications in Proceedings (ASCO/ESMO Abstracts)

Prognostic factors influencing progression-free survival in HER2 positive metastatic breast cancer patients who treated with lapatinib and capecitabine combination

• Authors: Dogan, I., Paksoy, N., Ak, N., Vatansever, S., Saip, P., & Aydiner, A. (2022)

Efficacy of regorafenib and 5-fluorouracil-based rechallenge treatment in the third-line treatment of metastatic colorectal cancer: A Turkish oncology group study

• Authors: Şenocak Taşçi, E., Oyan, B., Sonmez, O., Mutlu, A. U., Atcı, M. M., Oner, I., ... & Gulmez, A. (2022)

Long-term outcomes and predictors of recurrence in patients with early-stage node-negative breast cancer

• Authors: Dogan, I., Aydin, E., Paksoy, N., Ferhatoglu, F., Ak, N., Ibis, K., ... & Aydiner, A. (2021)

Efficacy of temozolomide in pretreated patients with metastatic sarcoma

• Authors: Paksoy, N., Dogan, I., Ekenel, M., & Basaran, M. (2021)

Efficacy of sorafenib in symptomatic patients with pretreated progressive desmoid tumors

• Authors: Ferhatoglu, F., Paksoy, N., Dogan, I., Ak, N., Pehlivan, M., Ekenel, M., & Basaran, M. (2021)

Efficacy of sorafenib in heavily pretreated adult patients with metastatic osteosarcoma

• Authors: Paksoy, N., Dogan, I., Ekenel, M., & Basaran, M. (2021)

Outcomes and prognostic factors in metastatic renal cell carcinoma patients with brain metastases

• Authors: Dogan, İ., Iribas, A., Paksoy, N., Ekenel, M., Vatansever, S., & Basaran, M. (2021)

Association of response to first-line chemotherapy with the efficacy of atezolizumab in patients with metastatic urothelial carcinoma

• Authors: Tural, D., Olmez, O. F., Sümbül, A. T., Artac, M., Ozhan, N., Akar, E., ... & Erman, M. (2021)

Safety and survival in adult women with platinum-sensitive relapsed BRCA mutant ovarian cancer: A study of patients in Olaparib Turkey Early Access Program—LynTurk study

• Authors: Esin, E., Ahmed, M. A., Yıldırım, H. Ç., Mandel, N. M., Erdemoglu, E., Sari, M., ... & Paydas, S. (2023)

Atezolizumab in patients with metastatic urothelial carcinoma who have progressed after first-line chemotherapy: Results of real-life experiences

• Authors: Tural, D., Ölmez, Ö. F., Sümbül, A. T., Artaç, M., Özhan, N., Akar, E., ... & Kılıçkap, S. (2021)

Dr. Muhammed Mustafa Atci is an Associate Professor of Medical Oncology at İstinye University, Liv Hospital Topkapı (2025–present). He previously served as Associate Professor and Education Coordinator at Prof. Dr. Cemil Taşcıoğlu City Hospital (2023–2025). He was also a Medical Oncologist there (2018–2021).

He has been a member of ASCO and the Turkish Society of Medical Oncology since 2018. He is the author or co-author of 19 peer-reviewed international papers on colon, breast, gastric, pancreatic, lung, thyroid, sarcoma, and colorectal cancers.

Notable works include a multicentre study on stage IIB colon cancer survival (Journal of Chemotherapy). He also studied the De Ritis ratio for lung metastasis in testicular cancer (Current Urology). His prognostic studies used PET/CT, MSI, lymph node ratio, and metabolic tumor volume.

Assoc. Prof. Ayşe İrem Yasin, M.D., is a medical oncologist who specializes in solid tumors. Her clinical focus includes breast, lung, gastrointestinal, gynecologic, and urologic cancers. She also treats brain and other CNS tumors, soft tissue sarcomas, head and neck cancers, adenocarcinomas, melanoma, Merkel cell carcinoma, and cancers of unknown primary. She practices at Medipol Acıbadem District Hospital (2025–present). She previously worked at Şişli Etfal Training and Research Hospital (2023–2025).

She completed a Medical Oncology fellowship at Bezmialem Vakıf University (2019–2022). This followed an Internal Medicine residency at the same institution (2012–2016). Her international experience includes the Breast Cancer Unit at the University of Piemonte Orientale in Novara (2022). She also trained at Basel University Hospital, Cleveland Clinic, and Harvard Medical School. She holds the ESMO Board Certificate (2022).